ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients

Genes and Development

Volumn 27, Issue 6, 2013, Pages 683-698

  Baena, Esther ^a,b   Shao, Zhen ^a,b,c   Linn, Douglas E ^d   Glass, Kimberly ^c   Hamblen, Melanie J ^a,b,e   Fujiwara, Yuko ^a,b,e   Kim, Jonghwan ^a,b   Nguyen, Minh ^a,b   Zhang, Xin ^d   Godinho, Frank J ^a,b,e   Bronson, Roderick T ^b   Mucci, Lorelei A ^d   Loda, Massimo ^d   Yuan, Guo Cheng ^c   Orkin, Stuart H ^a,b,e   Li, Zhe ^a,b,d  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Androgen receptor; ERG; ETS transcription factor; ETV1; Metabolism; Pten

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TMPRSS2 PROTEIN; TRANSCRIPTION FACTOR ER81; TRANSCRIPTION FACTOR ERG; UNCLASSIFIED DRUG;

ANDROGEN METABOLISM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CELL IMMORTALIZATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; EPITHELIUM CELL; FLOW CYTOMETRY; GENE ACTIVATION; GENE DELETION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE LOCUS; GENE LOSS; GENE OVEREXPRESSION; GENE TARGETING; GENETIC ENGINEERING; GENETIC TRANSCRIPTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOLOGY; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION;

ADENOCARCINOMA; ANDROGENS; ANIMALS; CELL LINE, TUMOR; CHROMATIN; DNA-BINDING PROTEINS; EPITHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; ONCOGENE PROTEINS; PROSTATE; PROSTATIC NEOPLASMS; SERINE ENDOPEPTIDASES; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS;

EID: 84875333536     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.211011.112     Document Type: Article

References (72)

1. Attard G, Clark J, Ambroisine L, Fisher G, Kovacs G, Flohr P, Berney D, Foster CS, Fletcher A, Gerald WL, et al. 2008a. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 27: 253-263.
2. Attard G, Clark J, Ambroisine L, Mills IG, Fisher G, Flohr P, Reid A, Edwards S, Kovacs G, Berney D, et al. 2008b. Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer. Br J Cancer 99: 314-320.
3. Bauer DE, Hatzivassiliou G, Zhao F, Andreadis C, Thompson CB. 2005. ATP citrate lyase is an important component of cell growth and transformation. Oncogene 24: 6314-6322.
4. Bismar TA, Dolph M, Teng L-H, Liu S, Donnelly B. 2012. ERG protein expression reflects hormonal treatment response and is associated with Gleason score and prostate cancer specific mortality. Eur J Cancer 48: 538-546.
5. Bolstad BM, Irizarry RA, Astrand M, Speed TP. 2003. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19: 185-193.
6. Cai C, Hsieh C-L, Omwancha J, Zheng Z, Chen S-Y, Baert J-L, Shemshedini L. 2007. ETV1 is a novel androgen receptorregulated gene that mediates prostate cancer cell invasion. Methods Enzymol 21: 1835-1846.
7. Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A, Alimonti A, Nardella C, Varmeh S, Scardino PT, et al. 2009. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 41: 619-624.
8. Casey OM, Fang L, Hynes PG, Abou-Kheir WG, Martin PL, Tillman HS, Petrovics G, Awwad HO, Ward Y, Lake R, et al. 2012. TMPRSS2-driven ERG expression in vivo increases self-renewal and maintains expression in a castration resistant subpopulation. PLoS ONE 7: e41668.
9. Chi P, Chen Y, Zhang L, Guo X, Wongvipat J, Shamu T, Fletcher JA, Dewell S, Maki RG, Zheng D, et al. 2010. ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature 467: 849-853.
10. Cline MS, Smoot M, Cerami E, Kuchinsky A, Landys N, Workman C, Christmas R, Avila-Campilo I, Creech M, Gross B, et al. 2007. Integration of biological networks and gene expression data using Cytoscape. Nat Protoc 2: 2366-2382.
11. de Boer E, Rodriguez P, Bonte E, Krijgsveld J, Katsantoni E, Heck A, Grosveld F, Strouboulis J. 2003. Efficient biotinylation and single-step purification of tagged transcription factors in mammalian cells and transgenic mice. Proc Natl Acad Sci 100: 7480-7485.
12. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG. 2007. Inflammation in prostate carcinogenesis. Nat Rev Cancer 7: 256-269.
13. Demichelis F, Fall K, Perner S, Andren O, Schmidt F, Setlur SR, Hoshida Y, Mosquera J-M, Pawitan Y, Lee C, et al. 2007. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26: 4596-4599.
14. Dentelli P, Del Sorbo L, Rosso A, Molinar A, Garbarino G, Camussi G, Pegoraro L, Brizzi MF. 1999. Human IL-3 stimulates endothelial cell motility and promotes in vivo new vessel formation. J Immunol 163: 2151-2159.
15. Dvorak HF. 1986. Tumors:Wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315: 1650-1659.
16. Ettinger SL. 2004. Dysregulation of sterol response elementbinding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Res 64: 2212-2221.
17. Glinsky GV. 2004. Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 113: 913-923.
18. Gopalan A, Leversha MA, Satagopan JM, Zhou Q, Al-Ahmadie HA, Fine SW, Eastham JA, Scardino PT, Scher HI, Tickoo SK, et al. 2009. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res 69: 1400-1406.
19. Grasso CS, Wu Y-M, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, et al. 2012. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487: 239-243.
20. Gupta S, Iljin K, Sara H, Mpindi JP, Mirtti T, Vainio P, Rantala J, Alanen K, Nees M, Kallioniemi O. 2010. FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-tomesenchymal transition in human prostate cancer cells. Cancer Res 70: 6735-6745.
21. Haffner MC, Aryee MJ, Toubaji A, Esopi DM, Albadine R, Gurel B, Isaacs WB, Bova GS, Liu W, Xu J, et al. 2010. Androgeninduced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet 42: 668-675.
22. Han G, Buchanan G, Ittmann M, Harris JM, Yu X, Demayo FJ, Tilley W, Greenberg NM. 2005. Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proc Natl Acad Sci 102: 1151-1156.
23. Hermans KG, Boormans JL, Gasi D, van Leenders GJHL, Jenster G, Verhagen PCMS, Trapman J. 2009. Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer. Clin Cancer Res 15: 6398-6403.
24. Hollenhorst PC, Ferris MW, Hull MA, Chae H, Kim S, Graves BJ. 2011. Oncogenic ETS proteins mimic activated RAS/ MAPK signaling in prostate cells. Genes Dev 25: 2147-2157.
25. Holzer RG, Ryan RE, Tommack M, Schlekeway E, Jorcyk CL. 2004. Oncostatin Mstimulates the detachment of a reservoir of invasive mammary carcinoma cells: Role of cyclooxygenase-2. Clin Exp Metastasis 21: 167-176.
26. Hoogland AM, Jenster G, van Weerden WM, Trapman J, van der Kwast T, Roobol MJ, Schröder FH, Wildhagen MF, van Leenders GJ. 2012. ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer. Mod Pathol 25: 471-479.
27. Huang DW, Sherman BT, Lempicki RA. 2009. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57.
28. Jacquinet EE, Rao NVN, Rao GVG, Hoidal JRJ. 2000. Cloning, genomic organization, chromosomal assignment and expression of a novel mosaic serine proteinase: Epitheliasin. FEBS Lett 468: 93-100.
29. Jane-Valbuena J, Widlund HR, Perner S, Johnson LA, Dibner AC, Lin WM, Baker AC, Nazarian RM, Vijayendran KG, Sellers WR, et al. 2010. An oncogenic role for ETV1 in melanoma. Cancer Res 70: 2075-2084.
30. Johnson WE, Li W, Meyer CA, Gottardo R, Carroll JS, Brown M, Liu XS. 2006. Model-based analysis of tiling-arrays for ChIP-chip. Proc Natl Acad Sci 103: 12457-12462.
31. Kim J, Bhinge AA, Morgan XC, Iyer VR. 2004. Mapping DNAprotein interactions in large genomes by sequence tag analysis of genomic enrichment. Nat Methods 2: 47-53.
32. Kim J, Chu J, Shen X, Wang J, Orkin SH. 2008. An extended transcriptional network for pluripotency of embryonic stem cells. Cell 132: 1049-1061.
33. Kimura T, Furusato B, Miki J, Yamamoto T, Hayashi N, Takahashi H, Kamata Y, van Leenders GJ, Visakorpi T, Egawa S. 2012. Expression of ERG oncoprotein is associated with a less aggressive tumor phenotype in Japanese prostate cancer patients. Pathol Int 62: 742-748.
34. King JC, Xu J, Wongvipat J, Hieronymus H, Carver BS, Leung DH, Taylor BS, Sander C, Cardiff RD, Couto SS, et al. 2009. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet 41: 524-526.
35. Klezovitch O, Risk M, Coleman I, Lucas JM, Null M, True LD, Nelson PS, Vasioukhin V. 2008. A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci 105: 2105-2110.
36. Krazeisen A, Breitling R, Imai K, Fritz S, Möller G, Adamski J. 1999. Determination of cDNA, gene structure and chromosomal localization of the novel human 17β-hydroxysteroid dehydrogenase type 7(1). FEBS Lett 460: 373-379.
37. Kunderfranco P, Mello-Grand M, Cangemi R, Pellini S, Mensah A, Albertini V, Malek A, Chiorino G, Catapano CV, Carbone GM. 2010. ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer. PLoS ONE 5: e10547.
38. Lemmen JG, van den Brink CE, Legler J, van der Saag PT, van der Burg B. 2002. Detection of oestrogenic activity of steroids present during mammalian gestation using oestrogen receptor α-and oestrogen receptor β-specific in vitro assays. J Endocrinol 174: 435-446.
39. Lesche R, Groszer M, Gao J, Wang Y, Messing A, Sun H, Liu X, Wu H. 2002. Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene. Genesis 32: 148-149.
40. Lin C, Yang L, Tanasa B, Hutt K, Ju B-G, Ohgi KA, Zhang J, Rose DW, Fu X-D, Glass CK, et al. 2009. Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell 139: 1069-1083.
41. Markert EK, Mizuno H, Vazquez A, Levine AJ. 2011. Molecular classification of prostate cancer using curated expression signatures. Proc Natl Acad Sci 108: 21276-21281.
42. Minner S, Enodien M, Sirma H, Luebke AM, Krohn A, Mayer PS, Simon R, Tennstedt P, Muller J, Scholz L, et al. 2011. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res 17: 5878-5888.
43. Mulholland DJ, Tran LM, Li Y, Cai H, Morim A, Wang S, Plaisier S, Garraway IP, Huang J, Graeber TG, et al. 2011. Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell 19: 792-804.
44. Nam RK, Sugar L, Yang W, Srivastava S, Klotz LH, Yang L-Y, Stanimirovic A, Encioiu E, Neill M, Loblaw DA, et al. 2007. Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer 97: 1690-1695.
45. Oikawa T, Yamada T. 2003. Molecular biology of the Ets family of transcription factors. Gene 303: 11-34.
46. Pettersson A, Graff RE, Bauer SR, Pitt MJ, Lis RT, Stack EC, Martin NE, Kunz L, Penney KL, Ligon AH, et al. 2012. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: A cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prev 21: 1497-1509.
47. Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov JP. 2006. GenePattern 2.0. Nat Genet 38: 500-501.
48. Rossi S, Graner E, Febbo P, Weinstein L, Bhattacharya N, Onody T, Bubley G, Balk S, Loda M. 2003. Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res 1: 707-715.
49. Seth A, Watson DK. 2005. ETS transcription factors and their emerging roles in human cancer. Eur J Cancer 41: 2462-2478.
50. Setlur SR, Mertz KD, Hoshida Y, Demichelis F, Lupien M, Perner S, Sboner A, Pawitan Y, Andrén O, Johnson LA, et al. 2008. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst 100: 815-825.
51. Sharma NL, Massie CE, Ramos-Montoya A, Zecchini V, Scott HE, Lamb AD, Macarthur S, Stark R, Warren AY, Mills IG, et al. 2013. The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. Cancer Cell 23: 35-47.
52. Shin S, Kim T-D, Jin F, Van Deursen JM, Dehm SM, Tindall DJ, Grande JP, Munz J-M, Vasmatzis G, Janknecht R. 2009. Induction of prostatic intraepithelial neoplasia and modulation of androgen receptor by ETS variant 1/ETS-related protein 81. Cancer Res 69: 8102-8110.
53. Sleeman KE, Kendrick H, Robertson D, Isacke CM, Ashworth A, Smalley MJ. 2007. Dissociation of estrogen receptor expression and in vivo stem cell activity in the mammary gland. J Cell Biol 176: 19-26.
54. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG, Balk SP. 2006. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66: 2815-2825.
55. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. 2005. Gene set enrichment analysis: A knowledgebased approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci 102: 15545-15550.
56. Suh JH, Park J-W, Lee C, Moon KC. 2012. ERG immunohistochemistry and clinicopathologic characteristics in Korean prostate adenocarcinoma patients. Korean J Pathol 46: 423-428.
57. Swinnen JV, Vanderhoydonc F, Elgamal AA, Eelen M, Vercaeren I, Joniau S, Van Poppel H, Baert L, Goossens K, Heyns W, et al. 2000. Selective activation of the fatty acid synthesis pathway in human prostate cancer. Int J Cancer 88: 176-179.
58. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, et al. 2010. Integrative genomic profiling of human prostate cancer. Cancer Cell 18: 11-22.
59. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun X-W, Varambally S, Cao X, Tchinda J, Kuefer R, et al. 2005. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310: 644-648.
60. Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, Morris DS, Menon A, Jing X, Cao Q, Han B, et al. 2007. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 448: 595-599.
61. Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE, Cao Q, Prensner JR, Rubin MA, Shah RB, et al. 2008. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 10: 177-188.
62. Twiddy AL, Leon CG, Wasan KM. 2010. Cholesterol as a potential target for castration-resistant prostate cancer. Pharm Res 28: 423-437.
63. Vitari AC, Leong KG, Newton K, Yee C, O'Rourke K, Liu J, Phu L, Vij R, Ferrando R, Couto SS, et al. 2011. COP1 is a tumour suppressor that causes degradation of ETS transcription factors. Nature 474: 403-406.
64. Wang J, Rao S, Chu J, Shen X, Levasseur DN, Theunissen TW, Orkin SH. 2006. A protein interaction network for pluripotency of embryonic stem cells. Nature 444: 364-368.
65. Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Lupien M, et al. 2009. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138: 245-256.
66. Ward PS, Thompson CB. 2012. Metabolic reprogramming: A cancer hallmark even warburg did not anticipate. Cancer Cell 21: 297-308.
67. Wei G-H, Badis G, Berger MF, Kivioja T, Palin K, Enge M, Bonke M, Jolma A, Varjosalo M, Gehrke AR, et al. 2010. Genomewide analysis of ETS-family DNA-binding in vitro and in vivo. EMBO J 29: 2147-2160.
68. Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, Gingrich JR, Wei JT, Gilhooly P, Grob BM, et al. 2012. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 367: 203-213.
69. Wu X, Wu J, Huang J, Powell WC, Zhang JF, Matusik RJ, Sangiorgi FO, Maxson RE, Sucov HM, Roy-Burman P. 2001. Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev 101: 61-69.
70. Yu J, Yu J, Mani R-S, Cao Q, Brenner CJ, Cao X, Wang X, Wu L, Li J, Hu M, et al. 2010. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 17: 443-454.
71. Zadra G, Priolo C, Patnaik A, Loda M. 2010. New strategies in prostate cancer: Targeting lipogenic pathways and the energy sensor AMPK. Clin Cancer Res 16: 3322-3328.
72. Zong Y, Xin L, Goldstein AS, Lawson DA, Teitell MA, Witte ON. 2009. ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. Proc Natl Acad Sci 106: 12465-12470.